A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Condition(s)
Solid Tumor
Molecular Target(s)
PTCH1
Drug Classification(s)
Agents(s)
1403-0011 (Brightline-2)
Phase(s)
II
Mechanism of Action
ENV- 101, a potent Hedgehog (Hh) pathway inhibitor
Purpose
n/a
Location
Mary Crowley Cancer Research - Medical City Dallas
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.
7777 Forest Lane,
Building C-707
Dallas, TX 75230
972.566.3000